Working… Menu

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00665600
Recruitment Status : Completed
First Posted : April 24, 2008
Last Update Posted : February 22, 2012
Information provided by (Responsible Party):

Brief Summary:
To investigate the efficacy and safety of repeated dosing of Levalbuterol over 6 weeks of treatment in COPD.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Levalbuterol HCl Drug: Albuterol Sulfate Drug: Placebo Phase 3

Detailed Description:
This study is a multi-center, randomized, double-blind, placebo and active controlled, parallel-group study of adult subjects with COPD. Approximately 250 subjects will be enrolled to randomize at least 200 subjects. Study participation will consist of a total of six study visits over nine weeks for each subject. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 257 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
Study Start Date : February 2002
Actual Primary Completion Date : March 2003
Actual Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: 1
Levalbuterol 0.63 mg TID
Drug: Levalbuterol HCl
Levalbuterol 0.63 TID
Other Name: Xopenex HCl Inhalation Solution

Experimental: 2
Levalbuterol 1.25 mg TID
Drug: Levalbuterol HCl
Levabuterol 1.25 mg TID
Other Name: Xopenex HCl Inhalation Solution

Active Comparator: 3
Racemic Albuterol 2.5 mg TID
Drug: Albuterol Sulfate
Racemic albuterol 2.5 mg TID
Other Name: Ventolin Inhalation Solution

Placebo Comparator: 4
Placebo TID
Drug: Placebo
Placebo TID

Primary Outcome Measures :
  1. The primary efficacy endpoint was the time-normalized area under the percent change from visit predose in FEV1 curve (nAUC0-8 hours) averaged over the six week double-blind period. [ Time Frame: Days -21, -14, 0, 14, 28, and 42 ]

Secondary Outcome Measures :
  1. Spirometry parameters [ Time Frame: Days -21, -14, 0, 14, 28, and 42 ]
  2. Exacerbations of COPD [ Time Frame: Days -14, 0, 14, 28, 42 ]
  3. COPD symptom ratings [ Time Frame: Days 0, 14, 28, 42 ]
  4. Baseline dyspnea and transitional dyspnea indices [ Time Frame: Days 0, 14, 28, 42 ]
  5. Ipatropium Bromide MDI use [ Time Frame: Day 0, 14, 28, 42 ]
  6. Short acting Beta-agonist MDI use [ Time Frame: Days 0, 14, 28, 42 ]
  7. Subject and physician global evaluations [ Time Frame: Days 14, 28, 42 ]
  8. St. George's Hospital Respiratory Questionnaire (SGRQ). [ Time Frame: Days 0, 42 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects must be at least greater than or equal to 35 years of age at the time of consent.
  • Subjects must have a pre-established primary clinical diagnosis of COPD.
  • Subjects must have a baseline FEV1 less than or equal to 65%
  • Subjects must have a predicted and >0.70 Liter
  • subject was taking steroids (inhaled, oral, or nasal), short-acting xanthines, or leukotrienes, the dose must have been stable for 30 days
  • Subjects must have a FEV1/forced vital capacity (FVC) less than or equal to 70%
  • Subjects must have a greater than or equal to 15 pack-year smoking history
  • Subjects must have a baseline medical research council (MRC) dyspnea scale score greater than or equal to 2
  • Regular use of a prescribed therapy for control of COPD symptoms for 3 months prior to study entry.
  • No COPD exacerbations that have required an emergency room visit, hospital admission or intensive out-patient therapy within 1 month prior to study entry

Exclusion Criteria:

  • Females who are pregnant or lactating.
  • Concurrent requirement of oxygen therapy
  • Known history of asthma, or any chronic respiratory disease other than COPD (not including chronic bronchitis or emphysema).
  • Diagnosis of cancer within 5 years prior to study entry with the exception of non-melanoma skin cancer.
  • Lung resection of more than one full lobe.
  • Use of intravenous, intra-articular or intramuscular corticosteroids within 30 days of study entry
  • History of upper or lower respiratory infection within 14 days of study entry.
  • Participation in an investigational drug study within 30 days of study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00665600

Layout table for location information
United States, California
Carmichael, California, United States
Spring Valley, California, United States
United States, Colorado
Wheat Ridge, Colorado, United States
United States, Florida
Largo, Florida, United States
Miami, Florida, United States
Panama City, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Elk Grove Village, Illinois, United States
Hines, Illinois, United States
United States, Maryland
Wheaton, Maryland, United States
United States, Massachusetts
Springfield, Massachusetts, United States
United States, Michigan
Cadillac, Michigan, United States
United States, Missouri
Columbia, Missouri, United States
United States, Montana
Missoula, Montana, United States
United States, New Jersey
Springfield, New Jersey, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
United States, Ohio
Mogadore, Ohio, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, Texas
Austin, Texas, United States
San Antonio, Texas, United States
Canada, Alberta
Calgary, Alberta, Canada
Canada, Manitoba
Winnepeg, Manitoba, Canada
Canada, Ontario
Mississauga, Ontario, Canada
Toronto, Ontario, Canada
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Sunovion Identifier: NCT00665600    
Other Study ID Numbers: 051-914
First Posted: April 24, 2008    Key Record Dates
Last Update Posted: February 22, 2012
Last Verified: February 2012
Keywords provided by Sunovion:
Chronic Bronchitis
Chronic Emphysema
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Pharmaceutical Solutions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action